Navigation Links
Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
Date:3/21/2011

RICHMOND, Va., March 21, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).  

In 2010, Insmed initially submitted a regulatory filing to FDA requesting clearance to proceed with a Phase 2 clinical trial for ARIKACE in NTM.  FDA responded by suggesting that the Company could change the proposed Phase 2 trial to a primary efficacy study.  Based on this feedback, Insmed submitted its IND seeking FDA clearance to initiate a Phase 3 clinical trial of ARIKACE in NTM earlier in the first quarter of this year.

Development of the clinical program aimed at NTM infections was done in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.  According to Kenneth Oliver, M.D., M.P.H., staff pulmonologist in the NIAID Laboratory of Clinical Infectious Diseases, current NTM treatment requires lengthy multi-drug regimens that can be poorly tolerated and are often not very effective, especially in patients with severe disease or in those who have failed prior treatment attempts.

No new drugs have been assessed for NTM in a significant number of years. The sustained-release formulation of ARIKACE allows for targeting of the drug to the lungs and the site of disease.

"FDA clearance of our IND to conduct a pivotal Phase 3 clinical trial for ARIKACE in NTM is a critical step in continuing to advance our development plan for this compound," said Renu Gupta, M.D., Executive Vice President Development & Chief Medical Officer of Insmed.  "We continue to expect that patient accrual will begin in our Phase 3 clinical trials of ARIKACE in NT
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Insmed to Host Second Quarter 2009 Conference Call
3. Insmed Announces Addition to the Russell 3000(R) Index
4. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
5. Insmed CEO Resigns Due to Health Concerns
6. Insmed Announces First Quarter 2009 Financial Results
7. Insmed Regains NASDAQ Compliance
8. Insmed to Host First Quarter 2009 Conference Call
9. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
10. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
11. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... Aug. 27, 2014  A novel biomarker for ... physicians better identify early-stage disease, when treatment can ... to a new study in The Journal of ... DGX ) and other institutions found ... outperformed conventional antibody-serum testing, including rheumatoid factor (RF) ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... Research and Markets  has announced the ... Spectrometer Industry Report 2014" report to their offering. ... Spectrometer Industry Report 2014 is a professional and in-depth ... ratio mass spectrometer industry. The report provides ... applications and industry chain structure. The isotope ratio mass ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, Inc., ... an update to the World Health Organization (WHO) on ... at the 12th Meeting of the WHO Advisory Committee ... of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 ...
... SEATTLE, Nov. 17, 2010 Cell Therapeutics, Inc. ("CTI") ... Medicines Agency ("EMA") approved CTI,s Pixuvri (pixantrone dimaleate) Pediatric ... and solid tumors in children between the ages of ... (the "PDCO") of the EMA adopted an opinion agreeing ...
... Researchers have demonstrated a new imaging tool for ... hastening their use in creating a new class ... consume less power than today,s. The semiconducting ... replacing conventional silicon components and circuits. However, one ...
Cached Biology Technology:Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 2European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 3Imaging tool may aid nanoelectronics by screening tiny tubes 2Imaging tool may aid nanoelectronics by screening tiny tubes 3
(Date:8/27/2014)... invasive grass species frequently found in forests has created ... on American toads, a new University of Georgia study ... to the U.S. in the early 1900s, is one ... to more than a dozen states in the past ... and in forests, it can survive in widely diverse ...
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... that exists as five strains, none of which have ... the Sudan ebolavirus (SUDV). Although not the strain currently ... as recently as 2012. In a new study appearing ... now report a possible therapy that could someday help ... Sidhu, Jonathan Lai and colleagues explain that about 50-90 ...
Breaking Biology News(10 mins):More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... of British Columbia and the Child & Family Research Institute ... a type of T cell in type 1 diabetes that ... Also known as juvenile diabetes, type 1 diabetes is an ... with type 1 diabetes, the body attacks itself by destroying ...
... to the National Heart, Lung and Blood Institute, the average ... and 30 times a night. This lack of oxygen leads ... disease, an abnormal heart rhythm, or even a fatal cardiac ... exploring the changes in distinct brain regions that contribute to ...
... The National Institute of Environmental Health Sciences has ... Shaw for a five-year study of how the ... selection. The project reflects a changing ... advances in molecular toxicology, computational sciences and information ...
Cached Biology News:Researchers study sleep apnea and lack of oxygen 2Researcher awarded $2.27 million to study environmental effects on gene copy number 2Researcher awarded $2.27 million to study environmental effects on gene copy number 3Researcher awarded $2.27 million to study environmental effects on gene copy number 4
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: